stockrowCervoMed Inc.
CRVO Healthcare Biotechnology
CervoMed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, down 58.9% from fiscal 2024.
- Revenue
- −99.6%
- EPS
- +8.57%
- Free cash flow
- −6.20%
Quarter to June 2026, against a year earlier
Follow CRVO
Alert me
CervoMed Inc. (CRVO) EV/Sales
As of 6 November 2026, CervoMed Inc. (CRVO) trades at a EV/Sales of 0.6×. Over the past ten years it has ranged from −1.7× (December 2024) to 23.6× (March 2024); the current reading is higher than 76% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 15.9× | — |
| FY2024 | −0.7× | — |
| FY2023 | 7.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 15.9× | 61.38% |
| Sep 2025 | 9.8× | 113.85% |
| Jun 2025 | 4.6× | (25.42%) |
| Mar 2025 | 6.2× | — |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ATOS Atossa Therapeutics, Inc. compare | −174× |
| FLNA Cassava Sciences, Inc. compare | n/m |
| NXTC NextCure, Inc. compare | 0.4× |
| CRVO CervoMed Inc. | 0.6× |
| EVAX Evaxion A/S - Sponsored ADR compare | 1.4× |
| CELU Celularity, Inc. compare | 3.4× |
| IGC IGC Pharma, Inc. compare | 19.3× |
| CVM Cel-Sci Corporation compare | 27.6× |
| MCRB Seres Therapeutics, Inc. compare | 49.2× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)